Ibex Investors’s Scinai Immunotherapeutics SCNI Stock Holding History

Ibex Investors’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,224	Closed	-$12.6M	–	54
2020 Q3	$12.6M	Sell	3,224 -61	-2%	-$234K	6.64%	9
2020 Q2	$7.47M	Sell	3,285 -287	-8%	-$462K	3.55%	11
2020 Q1	$2.75M	Sell	3,572 -18	-0.5%	-$15.9K	2.77%	9
2019 Q4	$3.33M	Hold	3,590	–	–	0.06%	11
2019 Q3	$2.14M	Hold	3,590	–	–	0.13%	20
2019 Q2	$2.07K	Hold	3,590	–	–	0.17%	25
2019 Q1	$1.95M	Hold	3,590	–	–	0.17%	27
2018 Q4	$1.71M	Hold	3,590	–	–	0.28%	22
2018 Q3	$2.01M	Hold	3,590	–	–	1.12%	19
2018 Q2	$2.4M	Hold	3,590	–	–	1.36%	17
2018 Q1	$1.95M	Hold	3,590	–	–	1.61%	15
2017 Q4	$1.92M	Buy	+3,590	New	+$2.26M	1.12%	13

Other funds holding SCNI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $5.64B AUM

Ibex Investors's SCNI Position: Q4 2020 in Review

Ibex Investors sold out of Scinai Immunotherapeutics (SCNI) in Q4 2020, closing a stake of 3,224 shares — an estimated $12.6M sold.

Ibex Investors first reported a position in SCNI in Q4 2017 and held it in 12 quarters. The position peaked at $12.6M in Q3 2020. 13 funds tracked by Wall St. Rank hold SCNI as of Q4 2020.

Ibex Investors reported no remaining Scinai Immunotherapeutics position as of Q4 2020 after selling out during the quarter.
Ibex Investors sold 3,224 Scinai Immunotherapeutics shares in Q4 2020, an estimated $12.6M.
Ibex Investors first reported a position in Scinai Immunotherapeutics in Q4 2017 and held it in 12 quarters.
Ibex Investors's Scinai Immunotherapeutics position peaked at $12.6M in Q3 2020.
13 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2020.

Based on Ibex Investors's 13F filing for Q4 2020, filed 3 Feb 2021.